Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 323 of 5804
-
Immune-Boosting drug may help women with repeated IVF failure
Disease control Recruiting nowClinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Phase: PHASE2, PHASE3 • Sponsor: Fakih IVF Fertility Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Poop pills could help CAR t therapy work better for lymphoma patients
Disease control Recruiting nowThis phase II trial tests how well fecal microbiome transplantation works to remodel intestinal microbiota for patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) with exposure to high-risk antibiot…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Immunotherapy cocktail takes on tough throat cancer
Disease control Recruiting nowIn this study, the investigators designed a randomized, open-label, phase II clinical trial for high-risk locally advanced nasopharyngeal carcinoma (T4 or N3 or EBV DNA ≥1500 copies/ml, AJCC 9th edition) that is sensitive to chemotherapy and PD-1 monoclonal antibody therapy. The …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for Hard-to-Treat breast cancer: targeted combo enters final testing
Disease control Not yet recruitingNTQ1062-301 is a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of the small-molecule AKT inhibitor NTQ1062 combined with fulvestrant versus placebo combined with fulvestrant in patients with HR positive, HER2 negative, l…
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New weekly shot could boost weight loss for those still struggling on current meds
Disease control Recruiting nowThe main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last abo…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control Not yet recruitingBefotertinib is a third-generation EGFR-TKI independently developed in China. In first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations, it has demonstrated a median progression-free survival (PFS) of 22.1 months, representing the longest reported…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study is an open-label, prospective, phase 2, randomized controlled study to evaluate the efficacy and safety of apolitovorrelizumab (QL1706) in combination with platinum chemotherapy versus platinum chemotherapy in the treatment of advanced unresectable and or metastatic tr…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for brain cancer: Triple-Drug attack shows promise
Disease control Recruiting nowThis is a prospective, single-Arm, phase II clinical study evaluating the efficacy and safety of thiotepa in combination with pirtobrutinib (a BTK Inhibitor) and sintilimab (a PD-1 Inhibitor) for frail or relapsed/refractory primary or secondary central nervous system lymphoma.It…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Lab-Grown eye cells implanted to fight blindness
Disease control Not yet recruitingPhase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial (HiPSC-RPE) Cells Subretinal Transplantation in Late-Stage Age-Related Macular Degeneration(AMD) Patients
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Triple-Drug attack aims to beat rare lymphoma
Disease control Not yet recruitingExtranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens. Preclinical and clinical evidence suggests that PD-L1 is …
Phase: PHASE2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
CRISPR therapy takes on Drug-Resistant lung cancer in liver
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of EDB-102 Injection in patients with advanced non-small cell lung cancer (NSCLC) who have liver metastases. The study specifically targets patients harboring the EGFR-L858R mutation who h…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for hard-to-treat nose and throat cancer: targeted drug combo shows promise
Disease control Recruiting nowBased on the short-term efficacy and plasma EBV DNA levels following immuno-induction chemotherapy, patients with locally advanced nasopharyngeal carcinoma who derive different benefits from this treatment can be identified. For high-risk patients who do not respond to immuno-ind…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Home eye tests could save thousands from blindness
Diagnosis Recruiting nowThe vast majority of glaucoma cases in the United States go undetected and untreated until the late stages of the disease. Open-angle glaucoma is a progressive condition that is asymptomatic in its early to moderate stages and may be amenable to screening through telemedicine-bas…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
Exoskeleton breakthrough: walk Hands-Free after spinal injury?
Symptom relief Recruiting nowThis study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
Phase: NA • Sponsor: Wandercraft • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Could a 3-Week radiation course replace 6 weeks for head and neck cancer?
Disease control Recruiting nowHypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT f…
Phase: PHASE2, PHASE3 • Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Magnetic brain zaps may restore movement after stroke
Disease control ENROLLING_BY_INVITATIONStroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities. The goal of this proposal is to provide a first assessment of the feasibility and efficacy of an innovative non-invasive brain stimulat…
Phase: NA • Sponsor: Magnetic Tides • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immune cells engineered to hunt viruses show promise for transplant kids
Disease control Recruiting nowThe goal of this prospective clinical study is to evaluate the safety and efficacy of Multi-Virus Specific T cells (LB-DTK-MV) in pediatric patients with systemic viral infection, including CMV, EBV, and BKV, after allogeneic hematopoietic stem cell transplantation (allo-HSCT). T…
Phase: NA • Sponsor: LucasBio • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Hope for High-Risk families: drug aims to stop lung scarring before it starts
Prevention Recruiting nowThis study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Jul 25, 2026 00:00 UTC
-
Brain aneurysm showdown: which procedure is safer?
Disease control Recruiting nowBrief Summary: The goal of this clinical trial is to compare whether the traditional approach (stent-assisted coiling) is associated with a lower complication rate than flow diverter (Pipeline™) treatment for unruptured intracranial wide-neck bifurcation aneurysms. It will also …
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immune cell therapy shows promise for tough skin cancers
Disease control Recruiting nowThe purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has …
Phase: PHASE2 • Sponsor: Karam Khaddour, MD, MS • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC